Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Neuropathic Pain Market

ID: MRFR/HC/0881-CR
200 Pages
Nidhi Mandole
Last Updated: May 08, 2026

Neuropathic Pain Market Research Report By Type of Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Trigeminal Neuralgia, Chemotherapy-Induced Peripheral Neuropathy), By Treatment Type (Medications, Physical Therapy, Surgical Procedures, Electrical Stimulation), By Route of Administration (Oral, Topical, Injectable), By End User (Hospitals, Clinics, Home Care) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Neuropathic Pain Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type of Neuropathic Pain (USD Billion) | |
      1. 4.1.1 Diabetic Neuropathy | |
      2. 4.1.2 Postherpetic Neuralgia | |
      3. 4.1.3 Trigeminal Neuralgia | |
      4. 4.1.4 Chemotherapy-Induced Peripheral Neuropathy |
    2. 4.2 Healthcare, BY Treatment Type (USD Billion) | |
      1. 4.2.1 Medications | |
      2. 4.2.2 Physical Therapy | |
      3. 4.2.3 Surgical Procedures | |
      4. 4.2.4 Electrical Stimulation |
    3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.3.1 Oral | |
      2. 4.3.2 Topical | |
      3. 4.3.3 Injectable |
    4. 4.4 Healthcare, BY End User (USD Billion) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Clinics | |
      3. 4.4.3 Home Care |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Pfizer (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Eli Lilly (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bristol-Myers Squibb (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Astellas Pharma (JP) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Novartis (CH) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Johnson & Johnson (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 AbbVie (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 GSK (GB) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    7. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE |
    8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    9. 6.6 US MARKET ANALYSIS BY END USER |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    11. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    13. 6.10 CANADA MARKET ANALYSIS BY END USER |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    16. 6.13 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    18. 6.15 GERMANY MARKET ANALYSIS BY END USER |
    19. 6.16 UK MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    20. 6.17 UK MARKET ANALYSIS BY TREATMENT TYPE |
    21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    22. 6.19 UK MARKET ANALYSIS BY END USER |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    24. 6.21 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    26. 6.23 FRANCE MARKET ANALYSIS BY END USER |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    28. 6.25 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    30. 6.27 RUSSIA MARKET ANALYSIS BY END USER |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    32. 6.29 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    34. 6.31 ITALY MARKET ANALYSIS BY END USER |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    36. 6.33 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    38. 6.35 SPAIN MARKET ANALYSIS BY END USER |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    45. 6.42 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    47. 6.44 CHINA MARKET ANALYSIS BY END USER |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    49. 6.46 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    51. 6.48 INDIA MARKET ANALYSIS BY END USER |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    53. 6.50 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    55. 6.52 JAPAN MARKET ANALYSIS BY END USER |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY END USER |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    65. 6.62 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    67. 6.64 THAILAND MARKET ANALYSIS BY END USER |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    69. 6.66 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    71. 6.68 INDONESIA MARKET ANALYSIS BY END USER |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY END USER |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    78. 6.75 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    80. 6.77 BRAZIL MARKET ANALYSIS BY END USER |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    82. 6.79 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    84. 6.81 MEXICO MARKET ANALYSIS BY END USER |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY END USER |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF NEUROPATHIC PAIN |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY END USER |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE OF NEUROPATHIC PAIN, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE OF NEUROPATHIC PAIN, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY END USER, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY END USER, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY END USER, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY END USER, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY END USER, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY END USER, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY END USER, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY END USER, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY END USER, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY END USER, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY END USER, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY END USER, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY END USER, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY END USER, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY END USER, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY END USER, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY END USER, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY END USER, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY END USER, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY END USER, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY END USER, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY END USER, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY END USER, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY END USER, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY END USER, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY END USER, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY END USER, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE OF NEUROPATHIC PAIN, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY END USER, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type of Neuropathic Pain (USD Billion, 2025-2035)

  • Diabetic Neuropathy
  • Postherpetic Neuralgia
  • Trigeminal Neuralgia
  • Chemotherapy-Induced Peripheral Neuropathy

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Medications
  • Physical Therapy
  • Surgical Procedures
  • Electrical Stimulation

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Topical
  • Injectable

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Home Care

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions